FY2024 EPS Estimates for GeoVax Labs Lifted by Roth Capital

GeoVax Labs, Inc. (NASDAQ:GOVX) – Stock analysts at Roth Capital boosted their FY2024 earnings per share estimates for shares of GeoVax Labs in a research note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($4.30) for the year, up from their prior forecast of ($5.52). The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.10) per share. Roth Capital also issued estimates for GeoVax Labs’ Q4 2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $8.55 EPS.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same period in the previous year, the company earned ($4.80) EPS.

GOVX has been the subject of a number of other research reports. Noble Financial increased their price target on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Alliance Global Partners initiated coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research note on Friday. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and a consensus price target of $13.25.

GeoVax Labs Stock Performance

NASDAQ GOVX opened at $2.43 on Friday. The business has a 50 day moving average price of $2.37 and a two-hundred day moving average price of $2.61. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.